Our study indicated a tendency equivalent to that in the PACIFIC trial and the study reported by Hellyer et al.; all findings supported the view that consolidation durvalumab should not be administered to patients with stage III EGFR mutation-positive NSCLC, which was recommended by Aredo et al. [26] In our study, the incidence of DM remained high, even after the consolidation of durvalumab. This evidence concerns the gene EGFR and non-small cell lung carcinoma.